<DOC>
	<DOCNO>NCT00305864</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose motexafin gadolinium give together temozolomide radiation therapy see well work treat patient newly diagnose supratentorial glioblastoma multiforme gliosarcoma . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Motexafin gadolinium may help temozolomide work well make tumor cell sensitive drug . Radiation therapy use high-energy x-ray kill tumor cell . Motexafin gadolinium may also make tumor cell sensitive radiation therapy . Giving motexafin gadolinium together temozolomide radition therapy may kill tumor cell .</brief_summary>
	<brief_title>Motexafin Gadolinium , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme Gliosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose motexafin gadolinium ( MGd ) give concurrently temozolomide radiotherapy patient newly diagnose supratentorial glioblastoma multiforme ( GBM ) gliosarcoma . II . Estimate overall survival patient treat concurrent radiotherapy , temozolomide , MGd follow post-radiation temozolomide . III . Determine short- long-term adverse effect patient treat treatment . IV . Estimate progression-free survival patient newly diagnose supratentorial GBM gliosarcoma treat regimen . OUTLINE : This multicenter , dose-escalation study motexafin gadolinium ( MGd ) . PHASE I : Patients undergo radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Beginning night first dose radiotherapy end night last dose radiotherapy , patient receive concurrent oral temozolomide daily day 0-39 . Patients also receive MGd IV 30 minute prior radiotherapy daily day 1-5 8-12 day 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 , 36 , 38 , 40 . Beginning 28 day completion radiotherapy , patient receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-7 patient receive escalate dos MGd maximum tolerate dose ( MTD ) determine . The MTD define dose precede 6 eligible patient experience dose-limiting toxicity . PHASE II : Patients undergo radiotherapy receive temozolomide phase I . Patients also receive MGd phase I MTD determine phase I . After completion study treatment , patient follow every 2 month 1 year , every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>Histologically confirm glioblastoma multiforme ( GBM ) gliosarcoma Newly diagnose surgical biopsy excision within past 5 week Supratentorial location , determine follow : Contrastenhanced MRI perform preoperatively MRI perform postoperatively within 28 day prior study entry ( preferably within 72 hour surgery ) Postoperative scan require diagnosed stereotactic biopsy preoperative MRI perform No glioma grade &lt; GBM No recurrent malignant glioma No tumor foci detect tentorium beyond cranial vault No multifocal disease leptomeningeal spread Zubrod performance status 01 Neurologic function status 02 Absolute neutrophil count ≥ 1,800 cells/mm^3 Platelet count ≥ 100,000 cells/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion allow ) BUN ≤ 25 mg/dL Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 2 time upper limit normal Fertile patient must use effective contraception 2 month completion study treatment Negative pregnancy test Not pregnant nursing No prior invasive malignancy , except nonmelanomatous skin cancer carcinoma situ uterine cervix bladder , unless diseasefree ≥ 3 year No severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require intravenous antibiotic study entry Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 day prior study entry Coagulation defect Known AIDS No prior allergic reaction study drug No history porphyria G6PD deficiency No allergy gadolinium contraindication MRI No concurrent chemotherapy Recovered effect surgery postoperative infection complication No prior systemic chemotherapy , include polifeprosan 20 carmustine implant ( Gliadel wafer ) , current GBM Prior chemotherapy different cancer allow No prior radiotherapy head neck ( except T1 glottic cancer ) would result overlap radiation therapy field No prophylactic filgrastim ( GCSF ) first course study treatment No concurrent sargramostim ( GMCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>